Recursion Pharmaceuticals, Inc. RXRX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total costs & expenses?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total costs & expenses of $134.98M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total costs & expenses changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total costs & expenses decreased by 34.5% year-over-year, from $206.11M to $134.98M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total costs & expenses?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s total costs & expenses has grown at a 39.1% compound annual growth rate (CAGR), from $192.95M to $722.81M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company to support its business activities during a specific period. It encompasses the cost of revenue, research and development expenditures, and general and administrative overhead required to sustain operations. Monitoring this figure is essential for assessing the company's overall burn rate and the efficiency of its capital allocation strategy in the drug discovery process.